Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc.이(가) 2026년 8월 4일에 보고한 내용

기업이 직접 제출한 8-K에서 가져왔습니다.

실적 발표 컨퍼런스 콜

Odyssey Therapeutics, Inc.의 실적 발표 콜 녹취록이 없습니다.

경영진의 발언

“Positive clinical proof-of-concept data for OD-001 marked an important milestone for Odyssey and we look forward to sharing additional, supportive data from this trial in October,”

발표 자료에서 그대로 인용했으며, 공시가 발언자를 실명으로 밝힌 경우에만 표시합니다.

주가는 어떻게 반응했나

실적 발표는 장 마감 후나 개장 전에 나오므로, 여기서 말하는 변동은 그다음 거래일입니다.

Odyssey Therapeutics, Inc.은(는) 무엇을 하는 기업인가

Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.

발표 자료 말미에 실린 기업 자신의 소개글입니다.